Alnylam Files for Initial Public Offering

Mar 01, 2004

NEW YORK, March 1 (GenomeWeb News) - Alnylam Pharmaceuticals has filed a statement with the SEC for an initial public offering, the company said Friday evening.

The number of shares of common stock Alnylam plans to offer, and their price, have yet to be determined. Bank of America Securities serves as the company's book-runner and lead manager.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

Science in Africa Unevenly Funded

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

Not Enough Progress?

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

This Week in Science

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.

Main menu